CMClarissa Mujacic

Clarissa Mujacic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Clarissa Mujacic has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Antonio Russo

    Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), University of Palermo, 90127 Palermo, Italy

    3 shared publications
  • Alessandro Perez

    Department of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology University of Palermo Italy

    2 shared publications
  • Antonio Galvano

    Department of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology University of Palermo Italy

    2 shared publications
  • Carla Ferrante Bannera

    Department of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology University of Palermo Italy

    2 shared publications
  • Emilia Di Giovanni

    Department of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology University of Palermo Italy

    2 shared publications
  • Enrico Di Marco

    Department of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology University of Palermo Italy

    2 shared publications

Latest Publications

  • Open Access

    Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

    by Clarissa Mujacic, Maria Concetta Vitale, Rita Siino, Emilia Di Giovanni, Carla Ferrante Bannera, Enrico Di Marco, Andrea Gottardo, Tancredi Didier Bazan Russo, Nadia Barraco, Alessandro Perez, et al.

    Endometriosis is a benign yet debilitating condition, and its molecular complexity remains unexplored. Although clinically recognized, its genetic landscape has long been overlooked. This review analyses cancer‐associated mutations (CAMs) identified in endometriotic lesions, revealing parallels with malignancy. Recurrent mutations in key oncogenic and tumour suppressor genes— PIK3CA , CTNNB1 , KRAS , PTEN and ARID1A —emerge with patterns distinct from cancer, yet suggesting shared mechanisms. Despite the limited genomic data, these findings position endometriosis as a valuable model for investigating early tumour‐like processes. By reframing endometriosis through the lens of molecular oncology, this study offers new insights into its pathogenesis and proposes a translational framework for advancing diagnostics and understanding disease progression at the benign–malignant interface.

  • Open Access

    Liquid biopsy: a new window on the BRCA genes

    by L. Incorvaia, V. Gristina, F. Pepe, T.D. Bazan Russo, M. Santoni, C. Mujacic, G. Curigliano, U. Malapelle, E.D. Capoluongo, A. Russo

  • Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer

    by Andrea Gottardo, Tancredi Didier Bazan Russo, Alessandro Perez, Marco Bono, Emilia Di Giovanni, Enrico Di Marco, Rita Siino, Carla Ferrante Bannera, Clarissa Mujacic, Maria Concetta Vitale, et al.

    The transformative role of artificial intelligence (AI) and multiomics could enhance the diagnostic and prognostic capabilities of liquid biopsy (LB) for lung cancer (LC). Despite advances, the transition from tissue biopsies to more sophisticated, non‐invasive methods like LB has been impeded by challenges such as the heterogeneity of biomarkers and the low concentration of tumour‐related analytes. The advent of multiomics – enabled by deep learning algorithms – offers a solution by allowing the simultaneous analysis of various analytes across multiple biological fluids, presenting a paradigm shift in cancer diagnostics. Through multi‐marker, multi‐analyte and multi‐source approaches, this review showcases how AI and multiomics are identifying clinically valuable biomarker combinations that correlate with patients' health statuses. However, the path towards clinical implementation is fraught with challenges, including study reproducibility and lack of methodological standardization, thus necessitating urgent solutions to solve these common issues.